Xeris Biopharma Holdings, Inc.
XERS
$4.16
$0.215.32%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 11.92% | -2.13% | 16.62% | 17.20% | 34.23% |
| Total Depreciation and Amortization | -4.07% | -4.87% | -1.02% | 2.93% | 3.88% |
| Total Amortization of Deferred Charges | 36.37% | 27.47% | 24.34% | 18.11% | 41.44% |
| Total Other Non-Cash Items | 79.24% | 184.06% | 1,009.98% | -19.11% | -51.46% |
| Change in Net Operating Assets | -40.13% | 134.18% | 85.79% | 107.79% | 82.09% |
| Cash from Operations | 21.36% | 55.41% | 48.76% | 48.91% | 54.30% |
| Capital Expenditure | 61.64% | 65.53% | 50.43% | -187.27% | -331.87% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 253.73% | 211.38% | 188.37% | 232.73% | -110.69% |
| Cash from Investing | 181.33% | 183.18% | 173.67% | 212.88% | -117.42% |
| Total Debt Issued | -- | 2.21% | 2.21% | 2.21% | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 198.28% | 30.03% | 30.03% | 25.60% | -98.12% |
| Repurchase of Common Stock | -270.07% | -268.71% | -284.85% | -291.26% | -115.60% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -898.40% | -21,593.33% | -441.10% | -3,028.85% | 78.89% |
| Cash from Financing | 2,342.28% | -29.20% | -29.01% | -28.86% | -101.27% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 107.45% | 138.12% | 125.11% | 123.91% | -192.54% |
